Use of metabolomics for the identification and validation of clinical biomarkers for preterm birth: Preterm SAMBA

dc.contributor.authorCecatti, Jose G.
dc.contributor.authorSouza, Renato T.
dc.contributor.authorSulek, Karolina
dc.contributor.authorCosta, Maria L.
dc.contributor.authorKenny, Louise C.
dc.contributor.authorMcCowan, Lesley M. E.
dc.contributor.authorPacagnella, Rodolfo C.
dc.contributor.authorVillas-Boas, Silas G.
dc.contributor.authorMayrink, Jussara
dc.contributor.authorPassini, Renato
dc.contributor.authorFranchini, Kleber G.
dc.contributor.authorBaker, Philip N.
dc.contributor.funderBrazilian National Research Council
dc.contributor.funderBill and Melinda Gates Foundation
dc.contributor.funderScience Foundation Ireland
dc.contributor.funderEnterprise Ireland
dc.contributor.funderFoundation for Research Science and Technology
dc.contributor.funderHealth Research Council of New Zealand
dc.contributor.funderEvelyn Bond Fund
dc.contributor.funderAuckland District Health Board Charitable Trust, New Zealand
dc.contributor.funderHealth Research Board
dc.description.abstractBackground: Spontaneous preterm birth is a complex syndrome with multiple pathways interactions determining its occurrence, including genetic, immunological, physiologic, biochemical and environmental factors. Despite great worldwide efforts in preterm birth prevention, there are no recent effective therapeutic strategies able to decrease spontaneous preterm birth rates or their consequent neonatal morbidity/mortality. The Preterm SAMBA study will associate metabolomics technologies to identify clinical and metabolite predictors for preterm birth. These innovative and unbiased techniques might be a strategic key to advance spontaneous preterm birth prediction. Methods/design: Preterm SAMBA study consists of a discovery phase to identify biophysical and untargeted metabolomics from blood and hair samples associated with preterm birth, plus a validation phase to evaluate the performance of the predictive modelling. The first phase, a case–control study, will randomly select 100 women who had a spontaneous preterm birth (before 37 weeks) and 100 women who had term birth in the Cork Ireland and Auckland New Zealand cohorts within the SCOPE study, an international consortium aimed to identify potential metabolomic predictors using biophysical data and blood samples collected at 20 weeks of gestation. The validation phase will recruit 1150 Brazilian pregnant women from five participant centres and will collect blood and hair samples at 20 weeks of gestation to evaluate the performance of the algorithm model (sensitivity, specificity, predictive values and likelihood ratios) in predicting spontaneous preterm birth (before 34 weeks, with a secondary analysis of delivery before 37 weeks). Discussion: The Preterm SAMBA study intends to step forward on preterm birth prediction using metabolomics techniques, and accurate protocols for sample collection among multi-ethnic populations. The use of metabolomics in medical science research is innovative and promises to provide solutions for disorders with multiple complex underlying determinants such as spontaneous preterm birth.en
dc.description.sponsorshipBrazilian National Research Council (Grand Challenges Brazil: Reducing the burden of preterm birth” number 05/2013); Bill and Melinda Gates Foundation (Award 401636/2013-5); Science Foundation Ireland (Program Grant for INFANT (12/RC/2272)); New Enterprise Research Fund; Foundation for Research Science and Technology; Health Research Council (04/198); Evelyn Bond Fund; Auckland District Health Board Charitable Trust; Health Research Board (CSA/2007/2)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.identifier.citationCecatti, J. G., Souza, R. T., Sulek, K., Costa, M. L., Kenny, L. C., McCowan, L. M., Pacagnella, R. C., Villas-Boas, S. G., Mayrink, J., Passini, R., Franchini, K. G. and Baker, P. N. (2016) 'Use of metabolomics for the identification and validation of clinical biomarkers for preterm birth: Preterm SAMBA', BMC Pregnancy and Childbirth, 16, 212 (9pp). doi: 10.1186/s12884-016-1006-9en
dc.identifier.journaltitleBMC Pregnancy and Childbirthen
dc.publisherBioMed Centralen
dc.rights© 2016, the Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.en
dc.subjectSpontaneous preterm birthen
dc.subjectBiological biomarkeren
dc.subjectMass spectrometryen
dc.titleUse of metabolomics for the identification and validation of clinical biomarkers for preterm birth: Preterm SAMBAen
dc.typeArticle (peer-reviewed)en
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
817.39 KB
Adobe Portable Document Format
Published Version